Vasopressin receptor antagonists in the management of acute heart failure

W. H Wilson Tang, Sanjeev Bhavnani, Gary S. Francis

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Vasopressin is a potent vasoconstrictor and plays a significant role in the regulation of volume homeostasis. Several non-peptide vasopressin receptor antagonists (vaptans) have emerged as promising drugs in the management of acute heart failure. Results of early trials with tolvaptan (selective vasopressin subtype 2 receptor antagonist) and conivaptan (dual vasopressin subtypes 1a and 2 receptor antagonist) have demonstrated improvement in the fluid status, osmotic balance and haemodynamic profile in patients with heart failure presenting with signs and symptoms of decompensation. Nevertheless, their comparative long-term safety and efficacy remains to be determined in large-scale clinical trials.

Original languageEnglish (US)
Pages (from-to)593-600
Number of pages8
JournalExpert Opinion on Investigational Drugs
Issue number5
StatePublished - May 2005


  • Acute heart failure
  • Fluid retention
  • Pharmacological therapy
  • Vaptan
  • Vasopressin


Dive into the research topics of 'Vasopressin receptor antagonists in the management of acute heart failure'. Together they form a unique fingerprint.

Cite this